CDC-RFA-TS19-19020301SUPP21: Early Detection of Certain Medical Conditions Related to Environmental Health Hazards Supplement
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Centers for Disease Control - ATSDR notices from 2021.
Centers for Disease Control - ATSDR offered grants of up to $999,999 (at least $999,999) to nonprofits and state and local governments. It expected to make one award worth $999,999 in total. Applications closed on June 26, 2021.
From the official notice on Grants.gov, last changed April 27, 2021. Checked November 7, 2026.
- Award ceiling$999,999
- Award floor$999,999
- Total funding$999,999
- Expected awards1
- Cost sharingNot required
- Funding typeGrant
Key dates
| Posted | April 27, 2021 |
|---|---|
| Deadline | June 26, 2021 |
| Archived by Grants.gov | July 26, 2021 |
Who can apply
This opportunity was open to nonprofits and state and local governments.
All 6 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Eligibility is limited - only current applicants funded under TS19-1902 will be considered eligible.
Is this a realistic fit?
- Past Affordable Care Act Program for Early Detection of Certain Medical Conditions Related to Environmental Health Hazards awards averaged $6.2 million; this notice allows up to $999,999 per award.
- Most of the program's money (100% over five years) went to nonprofits.
- No cost sharing or match is required.
What the grant funds
Libby, Montana was the site of a vermiculite mining and processing operation from the early 1920’s through 1990. While it was in operation, Libby was the world’s largest source of vermiculite. The commercial uses of vermiculite include insulation, fire proofing, and as a soil conditioner. Unfortunately, Libby vermiculite is contaminated with amphibole asbestos. This has resulted in asbestos-related morbidity and mortality in vermiculite workers, their family members, and residents with neither occupational nor para-occupational exposure. Reports of pervasive asbestos-related health outcomes in Libby prompted a concerted response by the federal government in 1999. A large component of this response was community-based screening conducted by the Agency for Toxic Substances and Disease Registry (ATSDR) in 2000 and 2001 in which 7,307 persons were screened. Additional screening was funded by ATSDR via a grant to the Montana Department of Health and Human Services 2003-2008 and to the Lincoln County Health Department 2009-2011. Libby was subsequently declared and environmental public health emergency and language was included in the Affordable Care Act (ACA, Public Law 111-148; https://www.hhs.gov/sites/default/files/ppacacon.pdf) to continue to make screening available to persons with potential past exposure to vermiculite while they resided in the Libby area. Persons with positive screening results may be eligible for Medicare benefits. The present notice of funding opportunity (NOFO) is to provide supplemental funding for screening activities currently being funded under the ACA. That screening program is expected to result in improved survival of participants with asbestos-related cancers, reduced rates of smoking-related diseases, and improved quality of life for participants.
Who has won Affordable Care Act Program for Early Detection of Certain Medical Conditions Related to Environmental Health Hazards grants before
From fiscal 2021 to 2025, Affordable Care Act Program for Early Detection of Certain Medical Conditions Related to Environmental Health Hazards (93.534) awarded $12.4 million across 2 grant awards, an average of $6.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Center for Asbestos Related Disease, Inc. | Montana | 2 | $12.4 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-TS19-19020301SUPP21 still open?
No. It closed on June 26, 2021.
Who can apply for Early Detection of Certain Medical Conditions Related to Environmental Health Hazards Supplement?
Centers for Disease Control - ATSDR accepted applications from nonprofits and state and local governments. The notice adds further conditions, so read its eligibility section.
What is the deadline for Early Detection of Certain Medical Conditions Related to Environmental Health Hazards Supplement?
Closed June 26, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $999,999 each. About $999,999 in total for one award.
Who has won Affordable Care Act Program for Early Detection of Certain Medical Conditions Related to Environmental Health Hazards grants before?
The largest recipients over five fiscal years were The Center for Asbestos Related Disease, Inc. The program made 2 awards worth $12.4 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)